The Latest Cardiac and Vascular News
CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks,…
– First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging – Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes
NEW YORK, April 20, 2026 /PRNewswire/ — Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by…
Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and […]
MADRID, April 17, 2026 /PRNewswire/ — Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, the first imageless, non-invasive cardiac mapping platform capable of delivering a global, four-chamber view of cardiac…
SOUTHLAKE, Texas & YOKNEAM, Israel–(BUSINESS WIRE)– #LVO–FDA clears TIGERTRIEVER™ 25 adjustable thrombectomy device by Rapid Medical; first U.S. cases show first-pass success in ischemic stroke.
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events In a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs. insulin glargine, showing the…
Among Nation’s First Programs to Offer the Innovative Procedure to Treat Valve Deformities in Children MIAMI, April 15, 2026 /PRNewswire/ — The cardiovascular surgery team at Nicklaus Children’s Hospital’s Heart Institute has successfully performed the first partial heart transplant in…
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced a multi-year agreement with Specialized Medical. Under this partnership, AccurKardia’s FDA-cleared Class II software as a medical device (SaMD), AccurECG™ 2.0, is actively powering Specialized Medical’s state-of-the-art cardiac monitoring operations, which currently serve more than 20 clinics, medical practices, and hospitals across four states. Specialized
